EMA Authorised: Giotrif (afatinib) — Boehringer Ingelheim International GmbH

View source ↗

Summary

EMA authorised Giotrif (afatinib) for non-small cell lung cancer, decision date 31 March 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Giotrif (afatinib)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Non-Small-Cell Lung. MAH: Boehringer Ingelheim International GmbH. Decision date: 31/03/2025